Stand up for our health and our economy.

Patient access to new medicines in Canada is in jeopardy. The federal government is planning to drastically change how drugs are regulated in Canada. If implemented, the proposed changes will not only limit access to the latest treatments, it will also lead to a decline in investment in Canada’s vibrant life sciences sector, bringing job losses and fewer clinical trials.

There's too much at stake for us to remain silent.
Help spread the word on how these changes will affect Canadians:

PMPRB changes put patient access to new medicines at risk.

Canadians are now among the first worldwide to benefit from new therapies. However, the proposed regulatory changes will slow down or limit patient access to new medicines.

Recent research from EY clearly demonstrates that market conditions matter when global companies decide where to launch new medicines. Aggressive cost containment policies in other countries like Australia and New Zealand have led to patients getting access to new medicines much later than other OECD countries or not at all. Click here for the study.

The PMPRB changes will make Canada a less attractive place to invest in high-value research – and that includes clinical trials. Clinical trials allow patients and the health system early access to new promising medicines.

PMPRB changes will harm Canada's competitiveness.

The pharmaceutical industry contributes to a strong economy by employing 13,000 Canadians directly, supporting over 30,000 jobs in total and driving over $19 billion in annual economic activity.

However, the proposed federal drug regulations will affect the pharmaceutical industry's financial capacity to continue to invest in Canada.

According to the PMPRB's own numbers, these changes would lead to price reductions of up to 70%, a cut that no industry could sustain.

If implemented, these changes will result in reduced health research investments and the loss of high-quality jobs. The reform will also have a devastating impact on the broader Canadian biosciences sector because it depends on investments from pharmaceutical companies to thrive.


  • Canada needs to read the fine print on pharma costs

    The proposed federal price controls for patented medicines will send the wrong signal to Canadian and global capital, meaning that companies will simply take their investments elsewhere.

    Financial Post

  • Ottawa's unhealthy drug 'fix'

    The federal government is changing regulatory guidelines used by the Patented Medicine Prices Review Board (PMPRB) to force lower prices for new drugs. At the same time, Ottawa is considering ways to implement national pharmacare, which the federal Liberals are expected to announce as part of their upcoming budget. The official justification for both is the same: the cost of pharmaceuticals.

    National Post

  • PM's pricing plan may limit access to new drugs

    It seems clear - the Trudeau government wants Ottawa to become the public insurer for prescription drugs, in part to contain drug costs. In 2017, the government proposed changes to the way it limits drug prices in Canada. While lower prices may seem like a good thing, there's a catch.

    The Province

  • Ottawa’s push for lower drug costs may hurt patients, stunt innovation

    The federal government’s plan to lower prescription drug prices could impede access and thus limit the benefits of life-saving drugs and discourage innovation, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.

    The Nelson Star

  • New PMPRB rules could impact patients with rare diseases: study

    The federal government’s plan to increasingly regulate pharmaceutical costs could mean Canadians with rare diseases may lose access to new innovative drug treatments, according to a new study by the Fraser Institute.

    Benefits Canada

  • Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective

    New drugs are emerging that promise improved treatments and in some cases even cures for diseases. But these drugs are expensive, and are heightening concerns from patients and insurers (particularly public insurers) about the prices that drug companies are asking for these medications.

    Fraser Institute

  • Prescription drug costs should be fair – not cheap

    A promise to bring down drug prices makes for a good sound bite, but what's more important is getting value for money.

    Globe & Mail

  • How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy

    Health policy in Canada is not evidence-based. For proof, look no further than the new drug-price regulations being implemented by the federal government, and its ongoing consideration of a new public monopoly drug-insurance program known as Pharmacare. The cost of patented drugs is the phony excuse driving both.

    Financial Post

  • The Trudeau government is building a wall to keep out life-saving drugs

    If you don’t know what the PMPRB is, you should — it holds the power of life and death over us

    Financial Post


    Le Conseil d’examen du prix des médicaments brevetés (CEPMB) a été créé en 1987. L’un des mandats du CEPMB est d’assurer que le prix des médicaments brevetés ne soit pas « excessif ». Une des façons d’évaluer le prix « excessif » est de vérifier si le prix du médicament au Canada est dans la médiane parmi sept pays de comparaison.

    La Presse

Media Contact

Sarah Dion-Marquis